VallerieVMcLaughlinMD
Cardiology • Ann Arbor, MIAdult Congenital Heart Disease
Professor, Internal Medicine, University of Michigan Medical School
Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Cardiovascular Disease, 1992 - 1995
University of MichiganResidency, Internal Medicine, 1989 - 1992- Northwestern University The Feinberg School of MedicineClass of 1989
Certifications & Licensure
MI State Medical License 1991 - 2025
IL State Medical License 1992 - 2005- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- Eisenmenger Quality Enhancement Research Initiative Start of enrollment: 2012 Jul 01
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.Stephan Rosenkranz, Hossein-Ardeschir Ghofrani, Marius M Hoeper, David Langleben, Sara Hegab
The Journal of Heart and Lung Transplantation. 2025-02-01 - Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.Marius M Hoeper, Mardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, Ekkehard Grünig
The European Respiratory Journal. 2025-01-30 - Highlights for the Heart Failure Cardiologist from the Seventh World Symposium on Pulmonary Hypertension: Are We Out of the Woods Yet?Thomas M Cascino, Bradley A Maron, Jean-Luc Vachiéry, Vallerie V McLAUGHLIN, Ryan J Tedford
Journal of Cardiac Failure. 2025-01-01
Lectures
- Relieving the Pressure of Pulmonary Arterial Hypertension: Key Takeaways for the General Cardiologist Moving from Vague Symptoms to Ensuring Adequate Treatment Response2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension: From Etiology to Therapy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Authored Content
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityFebruary 2018
Press Mentions
With Efficacy Assured, Merck Halts Another Trial of Blockbuster-to-Be WinrevairJanuary 30th, 2025- Merck to Stop Trial Evaluating Winrevair Pulmonary Arterial Hypertension EarlyJanuary 30th, 2025
- ZENITH Trial Breakthrough: Winrevair Shows Significant Impact on Outcomes of Pulmonary Arterial HypertensionDecember 4th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
